Association Between Sleep Quality and Cirrhotic Cardiomyopathy: A Prospective Case-Control Study
- PMID: 39659893
- PMCID: PMC11630714
- DOI: 10.2147/NSS.S482592
Association Between Sleep Quality and Cirrhotic Cardiomyopathy: A Prospective Case-Control Study
Abstract
Objective: The main purpose of this study is to evaluate the changes in sleep quality among patients with cirrhotic cardiomyopathy (CCM).
Methods: The study included liver cirrhosis patients aged 18-75 from Northern Jiangsu People's Hospital Affiliated to Yangzhou University and collected their clinical examination results to assess the clinical characteristics and related risk factors of patients with CCM.
Results: The study found that the onset of CCM was not related to the etiology of inducing cirrhosis. Pittsburgh Sleep Quality Index (PSQI) score (odds ratio (OR) = 13.476, 95% confidence interval (CI) = 1.514-119.923, P = 0.020), absolute GLS (OR = 0.328, 95% CI = 0.210-0.510, P < 0.001), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (OR = 1.050, 95% CI = 1.025-1.076, P < 0.001) were identified as independent risk factors for inducing CCM.
Conclusion: In patients with CCM, a decrease in sleep quality often occurs. When cirrhotic patients also have poor sleep quality, along with a decrease in absolute Global Left Ventricular Strain (GLS) levels and an increase in NT-proBNP levels, these factors may pose a higher risk for CCM development. However, further validation of these research findings is required in larger sample sizes.
Keywords: cardiomyopathy; cirrhotic cardiomyopathy; liver cirrhosis; sleep quality.
© 2024 Liu et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures



Similar articles
-
Left atrial strain and ventricular global longitudinal strain in cirrhotic patients using the new criteria of Cirrhotic Cardiomyopathy Consortium.Liver Int. 2023 Dec;43(12):2727-2742. doi: 10.1111/liv.15714. Epub 2023 Aug 29. Liver Int. 2023. PMID: 37641813
-
Left ventricular function is related with amphiregulin and fibrosis markers in cirrhotic cardiomyopathy.J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.10. Epub 2022 Jul 4. J Physiol Pharmacol. 2022. PMID: 35793762
-
Diagnosis and Management of Cirrhotic Cardiomyopathy.J Clin Exp Hepatol. 2022 Jan-Feb;12(1):186-199. doi: 10.1016/j.jceh.2021.08.016. Epub 2021 Aug 21. J Clin Exp Hepatol. 2022. PMID: 35068798 Free PMC article.
-
The Contemporary Role of Speckle Tracking Echocardiography in Cirrhotic Cardiomyopathy.Life (Basel). 2024 Jan 25;14(2):179. doi: 10.3390/life14020179. Life (Basel). 2024. PMID: 38398688 Free PMC article. Review.
-
Pediatric cirrhotic cardiomyopathy: literature review and effect size estimations of selected parameters.Eur J Pediatr. 2024 Nov;183(11):4789-4797. doi: 10.1007/s00431-024-05746-6. Epub 2024 Sep 4. Eur J Pediatr. 2024. PMID: 39227507 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous